Education
2004-2008 B.S., Xiamen University, China
2008-2010 M.S., Cell Biology and Innate Immunity, Wuhan University, China
2010-2013 Ph.D., Cell Biology and Innate Immunity, Wuhan University, China
Academic Experience
2013-2017 Postdoc Research Associate, University of North Carolina at Chapel Hill, USA
2017-2019 Research Assistant Professor, University of North Carolina at Chapel Hill, USA
2019- Professor, Medical Research Institute, Wuhan University, China
2019- Professor, Frontier Science Center for Immunology and Metabolism, Wuhan University, China
Research Areas
Our research interests involve the study of mechanisms of key signaling transduction pathways and how alterations in gene expression, post-translational modification or cell metabolism contribute to cancers.
Representative Publications
1. Zhang J*, Wu T*, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG Jr, Baldwin AS, Zhang Q. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018 Jul 20; 361(6399): 290-295.
· Highlighted by Sanchez DJ and Simon MC. Transcriptional control of kidney cancer.
Science 2018 Jul 20; 361(6399): 226-227. DOI: 10.1126/science.aau4385
· Commentary: ZHX2 is an oncogenic driver of kidney cancer. Cancer Discovery 2018
Jul 27 DOI: 10.1158/2159-8290.CD-RW2018-125
· Faculty1000 (Exceptional)
2.Jiang WW#, Zhang MY#, Gao C#, Yan CJ, Gao RH, He ZW, Wei X, Xiong JJ, Ruan ZL, Yang Q, Li JP, Li QF, Zhong ZY, Zhang MN, Yuan QQ, Hu HK, Wang S, Hu MM, Cai CG, Wu GS, Jiang C, Zhang YL, Zhang CS, Zhang J*. A mitochondrial EglN1-AMPKα axis drives breast cancer progression by enhancing metabolic adaptation to hypoxic stress. EMBO J. 2023, e113743: 1-20.
3.Yan C#, Xiong J#, Zhou Z#, Li Q#, Gao C, Zhang M, Yu L, Li J, Hu MM, Zhang CS, Cai C, Zhang H, Zhang J*. A cleaved METTL3 potentiates the METTL3–WTAP interaction and breast cancer progression. eLife. 2023, 87283: 1-25.
4.Yan C, Gao R, Gao C, Hong K, Cheng M, Liu X, Zhang Q* and Zhang J*. FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation. Frontiers in Oncology. 2023, 13: 1-12.
5.Xiong J, Yan C, Zhang Q* and Zhang J*. Alpha-ketoglutarate-dependent enzymes in breast cancer and therapeutic implications. Endocrinology. 2023, 164: 1-11.
6. Zhang J*, Wang C*, Chen X, Takada M, Fan C, Zheng X, Wen H, Liu Y, Wang CG, Pestell RG, Kaelin WG Jr, Liu XS and Zhang Q. EglN2 Associates with NRF-PGC1α Complex and Controls Mitochondrial Function in Breast Cancer. EMBO J. 2015 Dec 2; 34(23): 2953-70.
7. Zhang J, Hu MM, Shu HB, Li S. Death-associated protein kinase 1 is an IRF3/7-interacting protein that is involved in the cellular antiviral immune response. Cell Mol Immunol. 2014 May; 11(3): 245-52.
8. Zhang J, Hu MM, Wang YY, Shu HB. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J Biol Chem. 2012 Aug 17; 287(34): 28646-55.
9. Zhang J#, Zhang Q#. VHL and Hypoxia Signaling: Beyond HIF in Cancer. Biomedicines. 2018 Mar 19; 6(1). pii: E35.
10. Zhang J#, Zhang Q#. Using Seahorse Machine to Measure OCR and ECAR in Cancer Cells. Methods Mol Biol. 2019; 1928: 353-363.
11. Zhang J, Zheng X and Zhang Q. EglN2 positively regulates mitochondrial function in breast cancer. Mol Cell Oncol. 2015 Dec 22; 3(2): e1120845.
